ID | Components | Size |
---|---|---|
CMO-PAN001-C01 | SARS-CoV-2 Spike (WT) Fluc-GFP Pseudovirus | 96 Tests |
CMO-PAN001-C02 | HEK293/Human ACE2 Overexpression Stable Cell Line | 1 Vial |
CMO-PAN001-C03 | Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) | 100 ug |
The reagents provided are powerful tools for in vitro screening and characterization of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV-2 spike protein.
HEK293/Human ACE2 Overexpression Stable Cell Line is a stably transfected HEK293 cell line which stably overexpress human angiotensin I converting enzyme 2 (ACE2). Surface expression of ACE2 was confirmed by flow cytometry.
Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (AM122) is ideal as a positive control in SARS-CoV-2 (WT) Pseudovirus Neutralization Assay.
a. Though pseudovirus particles has no pathogenicity and cannot replicate, the assays should be carried out carefully in a Biosafety Level 2 or higher-level laboratory with a biosafety cabinet.
b. Serum samples from animals or humans should be inactivated in a water bath at 56 °C for 30 min before being tested.
c. Please avoid freezing and thawing, which would influence the titer of the pseudovirus.
d. The RLU could be influenced by multi-factors. If the detection reagent or luminescence meter other than those in this protocol is used, a pre-test should be carried out to determine an appropriate virus dosage per well.
e. The product is for Research Use Only.
Price(USD) : $2980.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.